Coxsackievirus B5 induced apoptosis of HeLa cells: Effects on p53 and SUMO  by Gomes, Rogério et al.
Virology 396 (2010) 256–263
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roCoxsackievirus B5 induced apoptosis of HeLa cells: Effects on p53 and SUMO
Rogério Gomes a,⁎, Renata Guerra-Sá b, Eurico Arruda a,c
a Department of Cell Biology, University of São Paulo School of Medicine at Ribeirão Preto, Av. dos Bandeirantes, 3900, 14049-900, SP, Brazil
b Federal University of Ouro Preto, MG, Brazil
c Virology Research Center, University of São Paulo School of Medicine at Ribeirão Preto, SP, Brazil⁎ Corresponding author. Fax: +55 16 3602 3376.
E-mail address: roggomes@usp.br (R. Gomes).
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.10.005a b s t r a c ta r t i c l e i n f oArticle history:
Received 27 July 2009
Returned to author for revision
27 September 2009
Accepted 3 October 2009
Available online 10 November 2009
Keywords:
Coxsackievirus B5
p53
SUMO
Apoptosis
UBC9Coxsackievirus B5 (CVB5), a human enterovirus of the family Picornaviridae, is a frequent cause of acute and
chronic human diseases. The pathogenesis of enteroviral infections is not completely understood, and the
fate of the CVB5-infected cell has a pivotal role in this process. We have investigated the CVB5-induced
apoptosis of HeLa cells and found that it happens by the intrinsic pathway by a mechanism dependent on the
ubiquitin–proteasome system, associated with nuclear aggregation of p53. Striking redistribution of both
SUMO and UBC9 was noted at 4 h post-infection, simultaneously with a reduction in the levels of the
ubiquitin-ligase HDM2. Taken together, these results suggest that CVB5 infection of HeLa cells elicit the
intrinsic pathway of apoptosis by MDM2 degradation and p53 activation, destabilizing protein sumoylation,
by a mechanism that is dependent on a functional ubiquitin–proteasome system.
© 2009 Elsevier Inc. All rights reserved.The human enteroviruses of the family Picornaviridae, are
distributes in 5 species: Poliovirus, Human enteroviruses A, B, C and D
(http://www.ncbi.nlm.nih.gov/ICTVdb/). A wide spectrum of human
diseases is caused by over 70 different serotypes of non-polio
enteroviruses, and coxsackie B viruses are among the most frequent
of them (Pallansch, 1997). Among the more extensively studied
coxsackie B viruses, coxsackievirus B5 (CVB5) is one of the most
importantly associated with human diseases, mainly affecting the
central nervous system (CNS), and the myocardium, but also in
association with long-term sequelae, such as insulin-dependent
diabetes mellitus and dilated cardiomyopathy (Endres et al., 2002;
Moschovi et al., 2002; Pallansch, 1997).
The progression of a viral infection ultimately results from the
interplay of virulence factors and the host immune system, frequently
leading to inﬂammatory responses that contribute to tissue damage.
Central to this is the fate of the infected host cell, which depends
mainly on the induction of apoptotic or necrotic cell deaths (McLean
et al., 2008). There is plenty of accumulated evidence that picorna-
viruses interfere with apoptosis (Buenz and Howe, 2006; Hwang et al.,
2007). Apoptosis is a programmed cell death, responsible for the
tissue remodeling, elimination of senescent and anomalous cells, and
also elimination of infected cells. It can be activated by extra cellular
(extrinsic pathway) or intracellular signals (intrinsic pathway). Both
pathways activate the cisteino proteases with speciﬁcity to arpartic
acid (caspases) (Danial and Korsmeyer, 2004). One of the key
molecules for apoptosis triggering is p53. The sequence-speciﬁcll rights reserved.DNA-binding transcription factor p53 has a central role in initiating
cell cycle arrest and apoptosis, principally through its ability to
increase the transcription of genes that control these processes
(Watson and Irwin, 2006). Pampin et al. (2006) have demonstrated
that Poliovirus infection induces the recruitment of p53 to promye-
locytic leukemia nuclear bodies (PML NBs), p53 phosphorylation on
Ser15, and activation of p53 target genes, leading to the induction of
p53-dependent apoptosis. The regulation of p53 activity and stability
is controlled by a series of post-translational modiﬁcations (phos-
phorylation, acetylaton, methylation, ubiquitination and sumoyla-
tion) (Lavin and Gueven, 2006). One mechanism of p53 regulation
involves the SUMO-speciﬁc protease SUSP4 which upregulates p53 by
promoting MDM2 self-ubiquitination and consequently degradation
by the proteasome complex (Lee et al., 2006). Viral interference with
the ubiquitination of host proteins could be beneﬁcial to the virus, as
long as it results in an environment that is more favorable for viral
propagation.
We describe in this paper the mechanisms of induction of
apoptosis by CVB5 in HeLa cells.
Results
Mitochondrial membrane potential change (ΔΨm) and cytochrome c
release
An increase inΨmwas observed by ﬂow cytometry of cells treated
with JC-1 at 4 h post-infection, indicating that CVB5 induced apoptosis
of HeLa cells (Fig. 1A). Release of cytochrome c from mitochondria to
cytosol at 4 h post-infection was evidenced by immunoblot (Fig. 1B).
Fig. 1. Activation of apoptotic intrinsic pathway by CVB5 infection of HeLa cells. Percentage of cells with depolarized mitochondria detected by cytoﬂuorimetric quantiﬁcation of JC-1
staining in CVB5- and mock-infected HeLa cells. Bivariate plots of orange (FL2) versus green (FL1) ﬂuorescence as an estimate of mitochondrial membrane potential variation
(ΔΨm). Values indicate percentages of cells with depolarized mitochondria (A). Western blot analysis shows that infection of CVB5 also causes release of cytochrome c (Cyt C) from
mitochondria to cytosol (B), and that procaspase 9 is cleaved into caspase 9 (C). Increase on caspase 3 activity was also observed by FACS analysis in CVB5 infected cells (D). Al those
events were observed at the time of 4 h post-infection.
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Fig. 2. CVB5 replication in HeLa cells causes p53 to aggregate in the nucleus: Mock- and CVB5-infected HeLa and Vero cells (MOI=10) were ﬁxed at 4 h post-infection and stained with
antibody to p53 andPML by immunoﬂuorescence. HeLa cellswere also incubatedwith the apoptosis inducer actinomycin D for 12 h and then ﬁxed. DAPIwas used to stain nuclei and images
wereobtainedby confocalmicroscopy.Aggregates of p53 formed in thenucleus of bothHeLa andVero cells (A), and thosedidnot colocalizewithPMLNB(B). Immunoblotdonewithantibody
to the p53 ubiquitin ligase MDM2, showed a decrease during the infection (C).
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tion of mitochondria and cytochrome c release to the cytosol.
Caspases 3 and 9
Western blot assay showed the cleavage of procaspase 9 into
caspase 9, noted at 4 h post-infection (Fig. 1C). This caspase 9
activation came along with an increase in caspase 3 activity detected
by FACS also at 4 h post-infection of HeLa cells by CVB5 (Fig. 1D).
p53 nuclear aggregation
In mock-infected HeLa cells, p53 staining was observed as a slight
diffuse signal throughout the cell. In contrast, in CVB5-infected cells
the p53 labelling was concentrated in dots within the nucleus. This
also occurred in HeLa cells treated with actinomycin D, an inductor of
apoptosis, as well as in Vero cells infected with CVB5 (Fig. 2A).
Possibly these nuclear aggregates could be a result of accumulation of
p53 on transcription sites of proapoptotic genes. No colocalization of
p53 nuclear aggregates with PML NB was observed on confocal
images (Fig. 2B). The detection by western blot of the p53 ubiquitin
ligase, MDM2, showed a decrease during the time course of CVB5
infection, better observed 4 h post-infection, as compared to mock
infected cells (Fig. 2C). The reallocation of p53 to nucleus could be a
consequence of MDM2 degradation which causes the release of p53 to
activation of proapoptotic genes.
SUMO and UBC9
In non-infected HeLa cells the SUMO E2 ligase UBC9 is localized as
an aggregate next to the nucleus, but at 4 h post-infection this
distribution is greatly altered, and appears dispersed throughout theFig. 3. CVB5 infection of HeLa cells causes conspicuous redistribution of SUMO-1 and UBC9
stained with antibodies to SUMO-1 and UBC9 by immunoﬂuorescence. DAPI was used to sta
UBC9 amounts were kept apparently constant during the infection (B).cell (Fig. 3A). Although the virus infection induced UBC9 dispersion
throughout the cell, the immunoblot assay indicated that the total
amount of UBC9 remained apparently constant during the experiment
(Fig. 3B). Similar to the ﬁndings with UBC9, SUMO is distributed
around the nucleus of non-infected HeLa cells, while in CVB5 infected
ones smaller aggregates of it were seen scattered throughout the cell
(Fig. 3A).
Inhibition of proteasome delays p53 nuclear aggregation during CVB5
infection
We have found that CVB5 progeny production in HeLa cells was
reduced in the presence of the proteasome inhibitors MG132 and PSI
in a dose- and time-dependent manner (data not shown). Here we
found that in cells incubated with 10 μM PSI, CVB5 infection did not
induce p53 nuclear doted aggregates observed in non-infected cells
(Fig. 4A). The absence of those aggregates could be a consequence of a
partial reduction of CVB5 replication in the presence of PSI (Fig. 4B), or
the nuclear aggregation of p53 could be dependent on a fully
functional proteasome.
Discussion
Several mechanisms of apoptosis induced by picornaviruses have
been documented (Buenz and Howe, 2006). For example, protease 3C
induces apoptosis in cells infected by poliovirus (Barco, Feduchi, and
Carrasco, 2000) and enterovirus 71 (Li et al., 2002). Likewise, the
Theiler's virus L protein interferes with nucleocytoplasmic trafﬁcking
(Delhaye, van Pesch, and Michiels, 2004), which could alter the
subcellular localization of proteins essential to the cell homeostasis,
such as nuclear factor-κB (NF-κB). Interestingly, CVB3 VP2 capsid
protein induces apoptosis via interaction with a CD27 cytoplasmic. Mock- and CVB5-infected HeLa cells (MOI=10) were ﬁxed at 4 h post-infection and
in nuclei and images were taken by confocal microscopy (A). Western blot shows that
Fig. 4. Inhibition of proteasome abrogates p53 nuclear aggregation in CVB5-infected cells. Mock- and CVB5-infected HeLa cells (MOI=10)were incubated with or without 10 μMPSI,
ﬁxed at 4 h post-infection, then stained with antibodies to p53 and CVB5 VP1 capsid protein by immunoﬂuorescence. DAPI was used to stain nuclei and images were obtained by
confocal microscopy (A). CVB5 titers were determined in the cell cultures by TCID50 (B).
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(Henke et al., 2000;Martin et al., 2004). The UPS is important for CVB3
replication, since proteasome inhibitors block the phosphorylation of
CVB3-induced extracellular signal-regulated kinase (ERK) through
the inhibition of degradation of mitogen-activated protein kinase
(MAPK) phosphatase-1 (MKP-1), resulting in reduced CVB3 replica-
tion (Wong et al., 2007).
The best-known mechanisms of immortalization of HeLa and Vero
cells involve degradation or inactivation of p53 (Ahuja, Saenz-Robles,
and Pipas, 2005; Scheffner and Whitaker, 2003). In HeLa cells, the
human papillomavirus (HPV) oncoprotein E6 binds to p53 and
stimulates its degradation by the UPS (Scheffner et al., 1990), while
in Vero cells the large T antigen of the polyomavirus SV40 binds to the
DNA-binding surface of p53, inhibiting its transcription activating
function (Ahuja, Saenz-Robles, and Pipas, 2005; Chen and Hahn,
2003). The differences between mechanisms of immortalization
might explain why the staining for p53 in HeLa cells showed amounts
generally reduced in comparison to the levels observed in Vero cells.
However, CVB5 infection was found to cause striking alteration in p53
distribution in both cell lineages, mainly characterized by the
formation of aggregates in the nucleus, probably equivalent to p53
docking sites for transcription of proapoptotic genes. While a CVB5product responsible for this effect has not yet been identiﬁed, this
ﬁnding strongly indicates that CVB5-induced apoptosis is p53-
dependent.
A wide spectrum of intrinsic and extrinsic stressors stabilize and
activate p53, affecting it byphosphorylation, acetylation, ubiquitination,
methylation and sumoylation (Lavin and Gueven, 2006). Such post-
translational modiﬁcations modulate levels of p53 and its trafﬁcking
between cell compartments, enabling induction of cell cycle arrest,
senescence or apoptosis, thus controlling the ultimate fate of the cell.
HDM2 (human double minute-2) is a homologue of MDM2 (mouse
double minute-2), which is a p53-speciﬁc E3 ligase responsible for the
regulation of p53, whose levels are also regulated by the UPS (Honda,
Tanaka, and Yasuda, 1997). Remarkably, the HDM2 gene is one of the
target genes whose transcription is activated by p53, and its product
regulates p53 by a feedback loop. The regulation of p53 by HDM2 and a
proposed model for how it can be affected by CVB5 infection are
summarized in Fig. 5. CVB5 infection ofHeLa cells causes deregulation of
protein sumoylation,which in turn leads to the availability of freeHDM2
for ubiquitination and degradation by the proteasome, (Buschmann et
al., 2000). HDM2 reduction leads to increased levels of p53, which is
thenmade available for nuclear translocation, stimulating the induction
of apoptosis.
Fig. 5. Model of p53 activation: HDM2 stability is sustained by a small ubiquitin-like modiﬁer (SUMO), which is attached to the target at the same lysine residues used for
ubiquitination, thus blocking HDM2 degradation (Ia), leaving p53 available for ubiquitination (Ib) and degradation by the proteasome (Ic). Exposure of the cell to CVB5 infection
would reduce sumoylation of HDM2 (IIa), leading to its ubiquitination (IIb) and proteasomal degradation, (IIc), ultimately causing p53 stabilization (IId) and its availability for nuclear
translocation and activation of proapoptotic genes (IIe). Small red circles represent SUMO; small green squares represent ubiquitin, small pink circles represent cytochrome c.
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appeared sharply perinuclear in control HeLa cells, was markedly
redistributed in CVB5 infected cells, appearing as dots dispersed
throughout the cell. Similarly, the SUMO-1 conjugating enzyme UBC9,
normally found concentrated at a restricted region near the nucleus,
was redistributed all over the cell upon CVB5 infection. These results
strongly indicate that CVB5 infection interferes with, and perhaps
destabilizes protein sumoylation in host cells. It has been shown that
other viruses, such as human cytomegalovirus, herpes simplex virus
and adenovirus, interfere with sumoylation of host proteins (Boggio
and Chiocca, 2005; Boggio and Chiocca, 2006). For example, the
protein Gam1 of avian adenovirus interferes with sumoylation,
causing degradation of UBC9 by a mechanism still not understood
(Chiocca, 2007). This interference with sumoylation caused by Gam1
leads to the disassembly of PML-NB, a structure that seems to have an
anti-virus function (Everett and Chelbi-Alix, 2007), thus helping
adenovirus replication (Colombo et al., 2002).
CVB5 infected cells had diminished levels of HDM2, which could
result from the transcriptional/translational shut-off of protein
synthesis, or from the HDM2 cleavage by a CVB5 protease.
In the light of the importance of the UPS for the regulation of p53
activity, and considering that UPS activity is intimately intertwined
with the efﬁcient replication of another coxsackie B virus, CVB3 (Gao
et al., 2008; Luo et al., 2003; Si et al., 2005; Si et al., 2007; Szalay et al.,
2006), it is noteworthy that in the present study a functional
proteasome was found to be essential for the CVB5-induced nuclear
translocation/aggregation of p53 in HeLa cells. It should be pointed
out that in the presence of a proteasome inhibitor that caused a lesser
than 10-fold reduction in CVB5 titers, there was a virtually completeabrogation of aggregation of p53 in the nucleus of HeLa cells.
Therefore, it is reasonable to say that a functional proteasome is
essential for the p53-dependent CVB5-induced apoptosis.
Alternatively, the stabilization of p53 in HeLa cells could be related
to the transcriptional/translational shutoffs of protein synthesis
caused by CVB5, which could in turn reduce levels of the protein E6
of HPV in HeLa cells and the large T antigen of SV40 in Vero cells, thus
leading to the stabilization of p53 levels. However, even in the
presence of higher levels of p53, a unifying mechanism must exist for
the nuclear translocation and for the conspicuous and apparently
targeted aggregation of p53 in the nucleus, both in HeLa and Vero cells
infected by CVB5. In summary, CVB5 infection triggers HeLa cell death
by apoptosis, which is associated with nuclear aggregation of p53 and
redistribution of SUMO, by a mechanism that is dependent on a
functional ubiquitin–proteasome system.
Materials and methods
Virus, cell culture, viral infections
CVB5 was originally a gift from Dr. Roger M. Loria (Virginia
Commonwealth University, Richmond, Virginia, USA) and further
propagated in the laboratory by standard protocols. HeLa and Vero
cells were grown in Dulbecco's modiﬁed minimal essential medium
with Eagle's salts (DMEM) supplemented with 10% fetal bovine serum
(FBS), to 80–90% conﬂuence prior to virus infection. Cells were
infected with CVB5 (MOI=10) for 1 h at 4 °C for virus adsorption.
Cells were then washed with PBS and cultured in DMEM supple-
mented with 2% FBS for the indicated periods of time.
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Rabbit polyclonal anti-UBC9 (H-81) and anti-p53 (FL-393), goat
polyclonal anti-SUMO-1 (N-19) and mouse monoclonal anti-MDM2
(SMP14) were all obtained from Santa Cruz (California). Both mouse
monoclonal anti-caspase 9 and anti-cytochrome c were obtained
from BD Pharmingen (California). Mouse monoclonal anti-enterovi-
rus was obtained from Dako (place). The mitochondrial potential
sensors JC-1 and secondary antibodies conjugated with Alexa 488 and
594 were obtained from Molecular Probes® (Oregon) and secondary
antibodies conjugated with HRP were obtained from Zymed (Cali-
fornia). The proteasome inhibitors PSI (Z-LLe-(OBut)-Ala-Leu-H) was
obtained from Biomol® International (Exeter).
Caspase 3 assay
HeLa cells (106 cells/ml) were collected at the indicated periods of
times. The rhodamine-labelled peptide substrate (Z-DEVD)2-Rh 110
(Calbiochem, Germany) was added to a ﬁnal concentration of 50 μM,
followed by incubation for 10 min at 37 °C. Cells were then washed in
PBS and resuspended in 300 μl of PBS for FACS analysis. The cellular
rhodamine 110 green ﬂuorescence (515–545 nm)wasmeasured with
excitation by a 488 nm argon laser on a FACScan ﬂow cytometer
(Becton Dickinson). A total of 104 cells per sample were analyzedwith
the WinMID® software.
JC1 assay
Changes in the mitochondrial membrane potential (ΔΨm)
consequent to mitochondrial dysfunction were evaluated using JC-1.
The accumulation of this compound in the mitochondrial matrix is
controlled by theΨm and its absorption/emission spectra is such that
color emission changes from green to orange as the Ψm increases
(Nicholls and Ward, 2000). CVB5 infected and control cells were
collected and washed with PBS, then resuspended in 300 μl of PBS and
incubated with 10 μg/ml of JC-1 for 10 min at 37 °C before analysis by
ﬂow cytometry. A total of 104 cells per sample were analyzed using
the WinMID® software.
Mitochondria enrichment
CVB5- or mock-infected HeLa cells were mechanically harvested
by scraping in PBS, centrifuged at 500×g for 5 min, the pellets were
resuspended in MB buffer (210 mM mannitol, 70 mM sucrose, 1 mM
EDTA, 10 mM HEPES pH 7.5) supplemented with of a cocktail of
protease inhibitors [phenylmethylsulfonyl ﬂuoride (PMSF), 1 mM;
leupeptine, 1 μg/ml; aprotinin, 6.8 mg/ml; benzamidine, 1 mM], and
then disrupted by several passages through a 25G1 needle ﬁtted onto
a 5-ml syringe. The suspensions obtained were centrifuged at 500×g
for 5 min at 4 °C and the supernatants were further centrifuged at
10,000×g for 30 min at 4°C, in order to obtain a pellet of heavy
membranes (HM) mitochondrial-enriched fraction, which was sup-
plemented with 1% Triton X-100. The supernatant was further
centrifuged at 100,000×g for 1 h at 4°C to obtain a supernatant of
the ﬁnal soluble cytosolic fraction (S), and a pellet of lightmembranes,
which was discarded. The fractions HM and S were stored at −70°
until further analysis.
Immunoblotting
Proteins separated by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) were transferred onto nitrocellulose
membranes, which were then blocked for 1 h with 3% nonfat dry milk
in 10 mM Tris-HCl pH 7,5 with 0.1% Tween 20. Blots were incubated
for 3 h with the appropriate primary antibody, followed by incubation
for 1.5 h with an adequate peroxidase-labelled secondary antibody.Immunoreactive bands were visualized by ECL Western Blotting
Detection Reagents (Amersham Biosciences®).
Immunoﬂuorescence
Cell culture monolayers grown on 12 mm glass coverslips inside
the wells of 24-well dishes were infected with CVB5 and ﬁxed at 4 h
postinfection in 2% paraformaldehyde for 20 min, rinsed three times
with PBS, permeabilized with 0.3% Triton X-100 in PBS for 15min, and
then blocked with 1% BSA in PBS for 1 h. Incubation with the primary
antibody diluted in PBS containing 1% BSA was done for 60 min,
followed by washing ten times with PBS, incubated with secondary
antibody for 45 min in 1% BSA/PBS, washed 10 times with PBS, and
mounted in Flourmount-G ® (Southern Biotech, place), all done at
room temperature. DNA was stained with DAPI (4′,6-diamidino-2-
phenylindole) and images were acquired using a Leica TCSP5 confocal
scanner microscope.
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